Everything below concerns methionine sulfoxide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
Dissolution is normally performed in water, phosphate-buffered saline, or normal saline, since the peptide is freely soluble in aqueous media and is rarely handled with strong organic solvents. Solution pH should be kept near neutral, because extreme acidity or alkalinity accelerates backbone hydrolysis and encourages oxidation of the methionine side chain. Once dissolved, the material is less stable than the dry powder and is commonly divided into single-use portions and frozen. Buffers containing primary amines, such as Tris, are often avoided because of possible side reactions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Free acid form of the heptapeptide; depends on terminal groups |
| Molecular mass | About 813.9 g/mol | Average mass used for mass spectrometry confirmation |
| Appearance | White to off-white solid | Supplied as a lyophilised powder; hygroscopic |
| Solubility class | Freely soluble in aqueous media | Water, saline, and phosphate buffers; limited organic solubility |
| Typical storage temperature | -20 degrees Celsius | Long term and dry; short working periods may use 2 to 8 degrees Celsius |
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
Semax is supplied as a lyophilized powder that appears white to off-white. It dissolves readily in water, phosphate-buffered saline, and other aqueous media, which simplifies preparation of working solutions for laboratory use. The nasal products registered in Russia are dilute aqueous solutions, typically around 0.1 percent peptide by weight. Organic solvents are rarely necessary and can complicate handling. Because the peptide is hygroscopic, weighing should be performed quickly and with minimal exposure to ambient humidity.
Solid material is normally kept at minus 20 degrees Celsius in a sealed, desiccated container. Reconstituted solutions are less stable and are usually divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of activity. Light exposure is minimized by using amber glassware or foil wrapping. Published stability data for this peptide are sparse, so recommended storage conditions rest mainly on general practice for short synthetic peptides rather than on dedicated study.
where the employee is in a position to objectively demonstrate that a report to her/his employer will prove ineffective, where the employee has to anticipate dismissal, where the employee must assume that the competent authority will be hindered in investigating the irregularity, or where there is a direct and serious hazard to life, to health, to safety, or to the environment. The draft does not improve on protection against dismissal for employees who report irregularities to their employer. The amendment does not provide for employees to anonymously file their observations of irregularities.
== External links == Table of radioactive isotopes, K-40 The Lund/LBNL Nuclear Data Search Potassium-40 Section, Radiological and Chemical Fact Sheets to Support Health Risk Analyses for Contaminated Areas
The coexistence of PPII and beta-turn play an important role of increasing entropy as resilin returns to its disordered form. The other function of PPII is to facilitate self-assembling process: it is found that the quasi-extended PPII is able to interact through an intermolecular reaction, and initiate the formation of fibrillar supramolecular structure.
Sources: en.wikipedia.org
June 19, 1987: Law concerning the duration and organization of working time. July 22, 1987: Law on the exercise of parental authority. July 18, 1988: Creation of the Secretary of State for Women's Rights, assigned to Michèle André. December 28, 1988: Order concerning the possession, distribution, dispensing, and administration of the drug Mifepristone 200 mg tablets. May 16, 1989: Decree removing the managerial and technical staff of the prison administration's external services from the list of positions for which separate recruitment could be planned for men and women. July 10, 1989: Framework law on education. July 10, 1989: Law on the prevention of child abuse and the protection of children. February 20, 1990: Order amending the order of November 3, 1988, concerning the prices of care and hospitalization related to voluntary termination of pregnancy. July 6, 1990: Law amending the Social Security Code and relating to family benefits and employment assistance for the care of young children. September 5, 1990: Marital rape is recognized for the first time by the Court of Cassation. December 21, 1990: The Council of State validates the conformity of the 1975 Veil Law with the European Convention on Human Rights. January 18, 1991: Law containing provisions relating to public health and social insurance. January 31, 1991: Decree concerning the responsibilities of the Secretary of State for Women's Rights and Daily Life, delegated by the Minister of Labour, Employment, and Vocational Training. May 1991: Édith Cresson becomes the first female Prime Minister of France.
=== 1. Gingiva === The gingiva is the visible soft-tissue component of the periodontium and forms a biological seal around the cervical region of the teeth, protecting the underlying periodontal structures from mechanical trauma and microbial invasion.
=== Citric acid cycle === α-Ketoglutarate is a component of the citric acid cycle, a cyclical metabolic pathway located in the mitochondria. This cycle supplies the energy that cells need by sequentially metabolizing (indicated by →) citrate through seven intermediate metabolites and then converting the eighth intermediate metabolite, oxaloacetate, back to citrate:
Sources: en.wikipedia.org
The catalytic activity of the resulting MOF was examined by carrying out alcohol oxidation with H2O2 as the oxidant. It also catalyzed the oxidation of primary alcohol, secondary alcohol and benzyl alcohols with high selectivity. Hill et al. have demonstrated the sulfoxidation of thioethers using a MOF based on vanadium-oxo cluster V6O13 building units. A MOF loaded with propylene oxide can act as a catalyst, converting CO2 into cyclic carbonates (ring-shaped molecules with many applications). They can also remove carbon from biogas. This MOF is based on lanthanides, which provide chemical stability. This is especially important because the gases the MOF will be exposed to are hot, high in humidity, and acidic. Triaminoguanidinium-based POFs and Zn/POFs are new multifunctional materials for environmental remediation and biomedical applications.
=== Second Military Occupation === Estrada Palma's presidency ended with the Little August War and his resignation in 1906. This began the Provisional Government of Cuba, a second period of military occupation by the United States in Cuba lasting until 1909. President Theodore Roosevelt was a highly active Freemason, but his first Provisional Governor William Howard Taft would not be initiated until 1909, several years after Taft left the country. No evidence exists to suggest that Taft was involved in the Brotherhood at this time. His successor, Charles Edward Magoon, was never a Freemason. In the 1908 Cuban general election, both of the leading Presidential candidates, from opposing political parties, were Freemasons; José Miguel Gómez of the Liberal Party, and Rafael Montoro, of the Conservative Party. They were featured on the cover of the Grand Lodge's bi-weekly magazine, La Gran Logia. From the leadership of the new independent Cuba had emerged two oppositional political ideologies for its direction, and the Grand Lodge of Cuba was then fractured in the same manner. A large portion of the Freemasonic leadership in Cuba promoted that "Masonic virtue," should be the guiding light for all of Cuba, not just for Freemasons. Like a half-century earlier, debates about if Freemasons should be involved in politics raged. On March 22, 1908, Grand Master Fernando Figueredo Socarás published a message complaining that the political situation in Cuba was hindering the work of the Grand Lodge, and that it had "corrupted everything, including Freemasonry...
=== Spain === All Spanish medical degree holders need to pass a competitive national exam (named 'MIR') in order to access the specialty training program. This exam gives them the opportunity to choose both the specialty and the hospital where they will train, among the hospitals in the Spanish Healthcare Hospital Network. Currently, medical specialties last from 4 to 5 years. There are plans to change the training program system to one similar to the UK's. There have been some talks between Ministry of Health, the Medical College of Physicians and the Medical Student Association but it is not clear how this change process is going to be.
Sources: en.wikipedia.org
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.
It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.
Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.
Dry powder is usually kept at about -20 degrees Celsius for long-term storage and at 2 to 8 degrees Celsius for short working periods. Containers should stay sealed and protected from light and moisture to limit degradation.